NASDAQ:FMTX

Forma Therapeutics Competitors

$25.65
-2.68 (-9.46 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$25.01
Now: $25.65
$28.52
50-Day Range
$24.58
MA: $31.54
$40.70
52-Week Range
$22.51
Now: $25.65
$56.33
Volume458,098 shs
Average Volume474,620 shs
Market Capitalization$1.21 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Forma Therapeutics (NASDAQ:FMTX) Vs. CBPO, ALLO, BEAM, IOVA, SWTX, and NSTG

Should you be buying FMTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Forma Therapeutics, including China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), and NanoString Technologies (NSTG).

China Biologic Products (NASDAQ:CBPO) and Forma Therapeutics (NASDAQ:FMTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares China Biologic Products and Forma Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.24$138.81 million$4.2827.63
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A

China Biologic Products has higher revenue and earnings than Forma Therapeutics.

Profitability

This table compares China Biologic Products and Forma Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
Forma TherapeuticsN/A-29.54%-20.61%

Analyst Recommendations

This is a breakdown of current ratings and price targets for China Biologic Products and Forma Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
Forma Therapeutics00603.00

Forma Therapeutics has a consensus price target of $61.6667, indicating a potential upside of 132.27%. Given Forma Therapeutics' higher probable upside, analysts clearly believe Forma Therapeutics is more favorable than China Biologic Products.

Insider and Institutional Ownership

34.8% of China Biologic Products shares are held by institutional investors. Comparatively, 67.3% of Forma Therapeutics shares are held by institutional investors. 2.7% of China Biologic Products shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

China Biologic Products beats Forma Therapeutics on 6 of the 10 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and Forma Therapeutics (NASDAQ:FMTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Allogene Therapeutics and Forma Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.73
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A

Forma Therapeutics has higher revenue and earnings than Allogene Therapeutics.

Profitability

This table compares Allogene Therapeutics and Forma Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
Forma TherapeuticsN/A-29.54%-20.61%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Allogene Therapeutics and Forma Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
Forma Therapeutics00603.00

Allogene Therapeutics presently has a consensus price target of $52.0833, indicating a potential upside of 60.55%. Forma Therapeutics has a consensus price target of $61.6667, indicating a potential upside of 132.27%. Given Forma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Forma Therapeutics is more favorable than Allogene Therapeutics.

Insider and Institutional Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Forma Therapeutics shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Forma Therapeutics beats Allogene Therapeutics on 6 of the 9 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Forma Therapeutics (NASDAQ:FMTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Forma Therapeutics shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Beam Therapeutics and Forma Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00227,047.22$-78,330,000.00($14.05)-5.17
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A

Forma Therapeutics has higher revenue and earnings than Beam Therapeutics.

Profitability

This table compares Beam Therapeutics and Forma Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
Forma TherapeuticsN/A-29.54%-20.61%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Beam Therapeutics and Forma Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Forma Therapeutics00603.00

Beam Therapeutics presently has a consensus price target of $96.00, indicating a potential upside of 31.18%. Forma Therapeutics has a consensus price target of $61.6667, indicating a potential upside of 132.27%. Given Forma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Forma Therapeutics is more favorable than Beam Therapeutics.

Summary

Forma Therapeutics beats Beam Therapeutics on 9 of the 11 factors compared between the two stocks.

Iovance Biotherapeutics (NASDAQ:IOVA) and Forma Therapeutics (NASDAQ:FMTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Iovance Biotherapeutics and Forma Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iovance BiotherapeuticsN/A-50.64%-45.64%
Forma TherapeuticsN/A-29.54%-20.61%

Insider & Institutional Ownership

94.6% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 67.3% of Forma Therapeutics shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Iovance Biotherapeutics and Forma Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iovance Biotherapeutics011002.91
Forma Therapeutics00603.00

Iovance Biotherapeutics presently has a consensus target price of $50.50, indicating a potential upside of 64.87%. Forma Therapeutics has a consensus target price of $61.6667, indicating a potential upside of 132.27%. Given Forma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Forma Therapeutics is more favorable than Iovance Biotherapeutics.

Earnings & Valuation

This table compares Iovance Biotherapeutics and Forma Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-18.96
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A

Forma Therapeutics has higher revenue and earnings than Iovance Biotherapeutics.

Summary

Forma Therapeutics beats Iovance Biotherapeutics on 6 of the 9 factors compared between the two stocks.

Forma Therapeutics (NASDAQ:FMTX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Forma Therapeutics and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forma TherapeuticsN/A-29.54%-20.61%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Insider & Institutional Ownership

67.3% of Forma Therapeutics shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Forma Therapeutics and SpringWorks Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forma Therapeutics00603.00
SpringWorks Therapeutics00403.00

Forma Therapeutics currently has a consensus target price of $61.6667, indicating a potential upside of 132.27%. SpringWorks Therapeutics has a consensus target price of $95.20, indicating a potential upside of 33.26%. Given Forma Therapeutics' higher possible upside, analysts plainly believe Forma Therapeutics is more favorable than SpringWorks Therapeutics.

Valuation and Earnings

This table compares Forma Therapeutics and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.12

Forma Therapeutics has higher revenue and earnings than SpringWorks Therapeutics.

Summary

Forma Therapeutics beats SpringWorks Therapeutics on 5 of the 8 factors compared between the two stocks.

Forma Therapeutics (NASDAQ:FMTX) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Forma Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forma TherapeuticsN/A-29.54%-20.61%
NanoString Technologies-53.47%-68.96%-24.15%

Insider & Institutional Ownership

67.3% of Forma Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Forma Therapeutics and NanoString Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forma Therapeutics00603.00
NanoString Technologies01402.80

Forma Therapeutics currently has a consensus target price of $61.6667, indicating a potential upside of 132.27%. NanoString Technologies has a consensus target price of $68.60, indicating a potential downside of 6.04%. Given Forma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Forma Therapeutics is more favorable than NanoString Technologies.

Valuation and Earnings

This table compares Forma Therapeutics and NanoString Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A
NanoString Technologies$125.57 million25.92$-40,700,000.00($1.93)-37.83

Forma Therapeutics has higher earnings, but lower revenue than NanoString Technologies.

Summary

Forma Therapeutics beats NanoString Technologies on 7 of the 11 factors compared between the two stocks.


Forma Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44-1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.69-1.5%$4.54 billion$20,000.00-5.17
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14-1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$71.44-3.0%$3.60 billionN/A-41.06Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01-1.6%$3.25 billion$125.57 million-42.70Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.60-3.5%$2.95 billionN/A0.00News Coverage
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67-18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49-0.7%$2.10 billion$31.43 million-5.13Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85-0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.28-5.1%$1.90 billion$44.67 million-2.58
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66-0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33-0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42-3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51-3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55-1.1%$1.40 billionN/A0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77-0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Up
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08-1.6%$623.24 million$13.29 million-9.99
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.59-0.8%$615.82 millionN/A0.00Analyst Downgrade
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.